Please assess the completion status of the following clinical trial:

Trial Title: Pre-op Paravertebral Blocks to Decrease Post-op Pain Following Mastectomy With Immediate Tissue Expander (TE) Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be Female aged 18-100 years.~* Choose mastectomy followed by bilateral immediate tissue expander breast reconstruction.~* Have no inflammatory breast cancers.~* Be aware of the nature of her malignancy.~* Understand the study purpose, requirements, and risks.~* Be able and willing to give informed consent.~Exclusion Criteria:~* Any concurrent opioid analgesic use (baseline opioid use must be 0 to be eligible).~* Liver dysfunction and/ or cirrhosis.~* Renal insufficiency, with creatinine greater than 1.5 mg/mL.~* Patients weighing less than 50 Kg.~* Concurrent use of the SSRI antidepressant fluvoxamine (Luvox).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine Group (Type: EXPERIMENTAL): Paravertebral block injections of study solution will occur using the landmark-based classic technique with a 22-gauge Tuohy needle to deliver 0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg).
- Saline Group (Type: PLACEBO_COMPARATOR): Paravertebral block injections of normal saline (up to 0.8 mL/kg) will occur using the landmark-based classic technique with a 22-gauge Tuohy needle. Immediately after completion of the injections, patients will be repositioned supine and general anesthesia induced in the standard manner.

Based on this trial design, predict the completion outcome and termination type (if applicable).